ClinicalTrials.gg
RecruitingNCT05238792ATTACKUpdated Oct 29, 2026

Multi Tumor-Associated Antigen-Specific T Lymphocytes to Treat Patients With High Risk Solid Tumors

A Phase 1 interventional study of Tumor-associated antigen-specific T cell (TAA-T) in Solid Tumor, sponsored by Children's National Research Institute. Recruiting at 1 site in United States. Open to participants aged 1 Year to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Children's National Research Institute · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2021; still recruiting 5 years later.
Updated Oct 29, 2026Enrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
1 Year to 70 Years
Sex
All
01

Study summary

This is an open-label phase I dose-escalation study to evaluate the safety of partially human leukocyte antigen (HLA)-matched multi tumor-associated antigen-specific T cell (TAA-T) therapy following lymphodepleting conditioning with or without local tumor ablation for pediatric and adult patients with high-risk solid tumors due to the presence of refractory, relapsed and/or minimal residual detectable disease following conventional therapy (e.g., chemotherapy, surgery, radiation, autologous stem cell transplant, or targeted therapy).

Read the detailed description

In this dose escalation trial, three dose levels will be tested for safety. TAA-T product will first be administered to patients as monotherapy at dose level 1 to determine safety.

All participants enrolled to DL2 or DL3 will be assigned to one of the following at Screening Eligibility:

  • Treatment Regimen 1 (Tx-R1): Lymphodepleting chemotherapy + TAA-T therapy
  • Treatment Regimen 2 (Tx-R2): Lymphodepleting chemotherapy + local tumor ablation with cryoablation or PEF (cryoablation/PEF) + TAA-T therapy

In this dose escalation trial, three dose levels will be tested for safety. The protocol-level accrual flow is described briefly as follows: TAA-T product will first be administered to adult patients (Arm A) as monotherapy at dose level 1 (Completed as of Protocol V5.0). Following demonstration of safety at DL1, adults will be enrolled at DL2. Following demonstration of safety at DL2 in adults, enrollment will proceed under the amended protocol to treatment regimens 1 and 2: Tx-R1 at DL3, and Tx-R2 at DL2 (upon approval of ATTACK Protocol V5.0).Tx-R1 and Tx-R2 may accrue in parallel to one another. Each regimen will independently escalate, expand, or de-escalate according to the 3+3 design until the MTD is identified or, if the MTD is not reached, the maximum administered dose, (MAD; DL3) is reached. A total of six patients will then be treated at each regimen's MTD (or MAD, as applicable).

Safety evaluations, including DLT assessment, maximum tolerated dose level (MTD) and recommended dose level (RDL) determination, will be performed separately for each regimen, however, if a protocol-defined stopping rule is met, enrollment and dosing in both regimens will be paused pending review.

The TAA-T product will be assessed for safety and anti-tumor activity.

02

Conditions studied

  • Solid Tumor
03

In context

Lead sponsor

Children's National Research Institute is the lead sponsor of 127 studies on the registry; 45 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of high-risk solid tumors known to express at least 2 targeted antigens by either histology or historical reference: Ewing sarcoma, Wilms tumor, neuroblastoma, rhabdomyosarcoma, soft tissue sarcoma, and osteosarcoma.
  • HLA type and match through at least one allele with antigen-specific activity.
  • Following conventional therapy: disease, residual detectable disease, or relapsed disease.
  • Age >= 1 year and \<70 years
  • Patient or parent/guardian capable of providing .
  • No systemic exposure within 1 week of initiating protocol treatment.
  • /Lansky score of ≥50%.
  • For participant with history of total body irradiation (TBI), radiation to thorax, or treatment with cardiotoxic chemotherapy (anthracycline or equivalent): (LVEF) >50% OR left ventricular fractional shortening (FS) >27% (may be performed within the last 12 months, and after completion of such treatment/s)
  • >7.0 g/dL (level can be achieved with transfusion).
  • Direct ≤2.5 mg/dL or 3x (whichever is higher).
  • (AST)/Alanine transaminase (ALT) ≤5 x the upper limit of normal for age.
  • Serum creatinine \<1.0 mg/dL or 2x the upper limit of normal for age (whichever is higher).
  • Pulse oximetry of >90% on room air.
  • Respiratory rate:
  • \<30 breaths per minute for patients aged \<18 years
  • \<25 breaths per minute for patients aged ≥18 years
  • Respiratory rate may be repeated if initial value is thought to be temporarily abnormal. If repeated, 2 values should be obtained ≥30 minutes apart prior to protocol treatment to be eligible.
  • Twelve (12) weeks post last radiation dose to the mediastinum/chest with resolution of any respiratory symptoms.
  • Negative pregnancy test in female patient of .
  • Agree to use measures during study protocol participation through 6 months post final TAAT infusion (for FOCBP).
  • Prior to cycle #1 only (requisite for receiving lymphodepleting chemotherapy):
  • (ANC) >1000 /ul.
  • count >75,000 /ul.

Exclusion criteria

Exclusion Criteria:

  • Patients with uncontrolled infections. Uncontrolled infections are defined as bacterial, fungal, or viral infections with either clinical signs of worsening despite standard therapy. Progressing infection is defined as hemodynamic instability, worsening physical signs, or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection.
  • For bacterial infections, patients must be receiving definitive therapy and have no signs of progressing infection within 7 days prior to protocol treatment.
  • For fungal infections, patients must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection within 7 days prior to initiating protocol treatment.
  • Patients who received ATG, Campath or other T cell monoclonal antibodies within 28 days prior to initiating protocol treatment.
  • Exposure to chemotherapy or immunomodulatory medications within the last 2 weeks prior to initiating protocol treatment.
  • Pregnant or lactating females.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
14 participants (estimated)

Study arms

  • Experimental
    TAA-T Infusion

    Treatment with partially human leukocyte antigen (HLA)-matched multi tumor-associated antigen-specific T cell (TAA-T) therapy following lymphodepleting conditioning with or without local tumor ablation.

    Biological: Tumor-associated antigen-specific T cell (TAA-T)

Interventions

  • BiologicalPatient-derived WT1/PRAME/Survivin-specific Cytotoxic T-lymphocytesStudies of Patient-derived WT1/PRAME/Survivin-specific Cytotoxic T-lymphocytesPatient-derived WT1/PRAME/Survivin-specific Cytotoxic T-lymphocytes pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will receive cells due to the presence of refractory disease, or high risk for disease relapse and/or minimal residual detectable disease following conventional therapy. The treatment schedule is as follows: Patients will receive an infusion of partially HLA-matched TAA-T any time \>1 week after completing most recent course of conventional (noninvestigational) therapy for their disease. For patients enrolled to DL2 or DL3, they will receive protocol-described lymphodepletion (LD) chemotherapy (fludarabine and cyclophosphamide) \>2 weeks from most recent course of conventional therapy and post nadir and recovery from the prior therapy. Patients will be enrolled to one of the following TAA-T dose levels: BSA \<1.20 Dose Level 2 (+/- ablation + low dose TAA-T cells) 2x10\^7 Dose Level 3 (+/- ablation + high dose TAA-T cells) 4x10\^7 BSA\>=1.20 Dose Level 2 (+/- ablation + low dose TAA-T cells) 4x10\^7 Dose Level 3 (+/- ablation + high dose TAA-T cells) 8x10\^7

06

What researchers measure

Primary outcomes

  1. To determine the safety of administering partially HLA-matched TAA-T cells

    Safety will be evaluated by the incidence of dose-limiting toxicities (DLTs).

    Time frame: 45 days

Secondary outcomes

  1. Treatment feasibility and impact of TAA-T infusion

    Determining anti-tumor activity (tumor response) following TAA-T infusion.

    Time frame: Within 12 months of TAA-T infusion

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2021 (actual). Primary completion is estimated for Oct 2028, 83 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2022
First posted
Feb 14, 2022
StartActual
Nov 17, 2021
Primary completionEst.
Oct 2028
CompletionEst.
Oct 2029
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
24→14
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Enrollment 24→14
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05238792
Responsible party
Amy Hont (Oncologist, Children's National Research Institute) — Principal investigator
First posted
Feb 14, 2022
Start date
Nov 17, 2021
Primary completion
Oct 2028 (estimated)
Completion
Oct 2029 (estimated)
Last update
Oct 29, 2026

Study contacts

Amy Hont, MD
Contact
ahoughte@childrensnational.org
202-476-3887
Fahmida Hoq, MBBS
Contact
fhoq@childrensnational.org
202-476-3634

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Patient-derived WT1/PRAME/Survivin-specific Cytotoxic T-lymphocytes

Start the discussion